Mountjaro is expected to be launched in Brazil. Know how much it will cost health
The pharmacist Eli Lily announced the expectation of the arrival of Mongoro (Tizerpatida) in Brazil. According to the company, the market will be provided with the drug until May 15. Before, the expectations were June 7.
“Based on the country, the product can arrive short or after it,” Felipe Pergo, Laila’s metabolism manager at a press conference on Friday, 25 years old.
Currently, the pens will only be available in doses of 2.5 and 5 milligrams in the country. The drug contains four other performances – transitions, 7.5 mg, 12.5 mg, two treatment, 10 mg and 15 mg – which does not have a specific date to reach Brazil.
The company has also announced the values that will be practiced in the country. For a box with four pens, which corresponds to one month of treatment, the price will vary from 1,406.75 dollars to $ 2,384.34, given the average of 18 % of the tax on the trading of goods and services (ICM) (read below).
The National Health Control Agency (AnVisa) gave the green light to Mounjaro in the treatment of type 2 diabetes in 2023. In other countries, as in the United States, it is also suitable for combating obesity, which is another chronic disease. The company submitted this nomination to the Gharb Anvisa and waited for the decision.
It can be used by adults, not recommended for children under the age of 18.
How much will it cost Monjaro?
Mounjaro will have two price systems. One in the pharmaceutical loyalty program, Lilly Best for You, which contains free adhesion – can be registered on this link – and another outside it.
According to the company, the loyalty program amounts will be valid for customers from all states, regardless of the ICMS rate.
Via Lilly is better for you, the values will be:
2.5 mg: t. $ 1,406.75 (e -commerce) / R.
Outside the program, values depend on ICMS for each state. Looking at an average of 18 %, the maximum prices that can be practiced in pharmacies will be:
2,5 MG: $ 1.907,29 5 MG: R $ 2.384,34
How Mounjaro works
It has active terracebatida, a substance, such as Smaglutida (OzemPIC and Wegovy), which are considered a ritual of the hormones of the intestine. However, unlike Semaglutide (which mimics the effects of LPG-1), the Mountjaro molecule has a similar action for two hormones: GLP-1 itself and also GIP (stomach inhibitors).
In this way, Tirzepatida is a dual riser. This work is similar to the stent in air damage, while controlling blood and satiety sugar levels. However, when hormones are operated simultaneously, their performance is strengthened. Therefore, in Eli Lilly Studies, Mountjaro was more effective than OzePic in reducing the level of glyclobin, a teacher indicating control of type 2 diabetes.
Mountjaro application weekly and rival subcutaneous, progressive dose. Treatment with tirzepatida should start with a dose of 2.5 mg and exceed 5 mg doses, 7.5 mg, 10 mg, 12.5 mg, until it reaches 15 mg. The drug should be used through medical follow -up, and can also provide side effects such as hypoglycemia, nausea and intestinal comfort.
